We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Targeting the Genes That Fuel Growth of Glioblastoma Multiforme
News

Targeting the Genes That Fuel Growth of Glioblastoma Multiforme

Targeting the Genes That Fuel Growth of Glioblastoma Multiforme
News

Targeting the Genes That Fuel Growth of Glioblastoma Multiforme

Credit: Robina Weermeijer/ Unsplash
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Targeting the Genes That Fuel Growth of Glioblastoma Multiforme"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Findings from a seven-year research project suggests that there could be a new approach to treating one of the most common and devastating forms of brain cancer in adults - Glioblastoma Multiforme (GBM).


In a peer-reviewed study published by BMC Cancerscientists from the University of Surrey show that a short chain of amino acids (the HTL-001 peptide) is effective at targeting and inhibiting the function of a family of genes responsible for the growth of GBM – Hox genes. The study was conducted in cell and animal models. 


The HTL-001 peptide used in the study has undergone safety testing and is suitable for patient trials. These trials are now being considered in GBM and other cancers.


Hardev Pandha, project lead and Professor of Medical Oncology at the University of Surrey, said:


"People who suffer from Glioblastoma Multiforme have a five per cent survival rate over a five-year period – a figure that has not improved in decades. While we are still early in the process, our seven-year project offers a glimmer of hope for finding a solution to Hox gene dysregulation, which is associated with the growth of GBM and other cancers, and which has proven to be elusive as a target for so many years."


Ironically, Hox genes are responsible for the healthy growth of brain tissue but are ordinarily silenced at birth after vigorous activity in the growing embryo. However, if they are inappropriately ‘switched on’ again, their activity can lead to the progression of cancer. Hox gene dysregulation has long been recognised in GBM. 


The project was carried out in collaboration with the universities of Surrey, Leeds and Texas, and HOX Therapeutics, a University of Surrey start-up company based on the University’s Surrey Research Park.


Professor Susan Short, co-author of the study from the University of Leeds, said:


"We desperately need new treatment avenues for these aggressive brain tumours. Targeting developmental genes like the HOX genes that are abnormally switched on in the tumour cells could be a novel and effective way to stop glioblastomas growing and becoming life-threatening."


James Culverwell, CEO of HOX Therapeutics, said:


“HOX Therapeutics is excited to be associated with this project and we hope that with our continuing support, this research will eventually lead to novel and effective treatments for both brain and other cancers where HOX gene over-expression is a clear therapeutic target.” 


Reference: Arunachalam E, Rogers W, Simpson GR, et al. HOX and PBX gene dysregulation as a therapeutic target in glioblastoma multiforme. BMC Cancer. 2022;22:400. doi: 10.1186/s12885-022-09466-8

  

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement